Raxone (idebenone) 150 mg tablets. FDA Approved

Raxone (idebenone) tablets can be ordered by patient or doctor, if the drug has not been approved or is not available in your country. Medvitaz Pharma Solutions can help you from India to get best price/cost of Raxone (idebenone) tablets to treat visual impairment in adults and adolescents aged 12 years.
Category: .

Raxone (idebenone) 150 mg film-coated tablets

Raxone (idebenone) is a prescription medicine. Raxone (idebenone) is used to treat visual impairment in adults and adolescents aged 12 years and over with Leber’s hereditary optic neuropathy (LHON), an inherited disease characterised by progressive loss of sight.
INDICATIONS AND USAGE
Raxone is indicated for the treatment of visual impairment in adolescent and adult patients with
Leber’s Hereditary Optic Neuropathy (LHON). Raxone contains a substance called idebenone. Idebenone is used to treat vision impairment in adults and adolescents with an eye disease called Leber’s Hereditary Optic Neuropathy (LHON).

  • This eye problem is inherited – this means it runs in families.
  • It is caused by a problem with your genes (called a “genetic mutation”) that affects the ability of cells in the eye to produce the energy they need to work normally, so they become inactive.
  • LHON can lead to loss of eyesight due to the inactivity of cells responsible for vision. Treatment with Raxone can restore the ability of cells to produce energy and so allow inactive eye cells to work again. This can lead to some improvement in lost eyesight.

DOSAGE FORMS & STRENGTHS
Each film-coated tablet contains 150 mg idebenone.
Manufactured By: Santhera Pharmaceuticals (Deutschland) GmbH
Prescribing Information URL: Click Here

Access to Raxone (idebenone) tablets Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from Medvitaz Pharma Solutions.

Idebenone (pronounced eye-deb-eh-known, trade names Catena, Raxone, Sovrima, among others) is a drug that was initially developed by Takeda Pharmaceutical Company for the treatment of Alzheimer's disease and other cognitive defects. It is approved by the European Medicines Agency (EMA) for use in Leber's hereditary optic neuropathy (LHON) and was designated an orphan drug in 2007.

Nootropic effects and Alzheimer's disease
Research on idebenone as a potential therapy of Alzheimer's disease have been inconsistent, but there may be a trend for a slight benefit. In May 1998, the approval for this indication was cancelled in Japan due to the lack of proven effects. In some European countries, the drug is available for the treatment of individual patients in special cases.

Friedreich's ataxia (Sovrima)
Preliminary testing has been done in humans and found idebenone to be a safe treatment for Friedreich's ataxia (FA), exhibiting a positive effect on cardiac hypertrophy and neurological function. The drug was approved for FA in Canada in 2008 under conditions including proof of efficacy in further clinical trials.

Leber's hereditary optic neuropathy (Raxone)
Leber's hereditary optic neuropathy (LHON) is a mitochondrially inherited (mother to all offspring) degeneration of retinal ganglion cells (RGCs) and their axons that leads to an acute or subacute loss of central vision; this affects predominantly young adult males.

Reviews

There are no reviews yet.

Add a review

neeraj
Neeraj Nagpal

Head of Operations

 The profound knowledge of more than 20 years in sales and marketing sector, he has been working dedicatedly and contributing to pharmaceuticals industry. He handles all operations over the country.

Contact Our Team

Contact us and we will reply as soon as possible!

    need help?

     MEDVITAZ is an initiative for helping end-users directly to get the right medicines and right medical treatments from the right source.